- Bruker Corporation (BRKR, Financial) showcases innovations at ASMS 2025, including the new timsMetabo™ platform for small molecule analysis.
- Integration with RECIPE’s ClinMass® and ClinDART® kits aims to enhance TDM and DoA applications.
- The timsMetabo™ platform offers significant improvements in PFAS detection and environmental contaminant analysis.
Bruker Corporation (BRKR) has unveiled a series of strategic innovations at the 73rd American Society for Mass Spectrometry (ASMS) Conference, held from June 1-5, 2025, in Baltimore, Maryland. Highlighting its commitment to applied markets, Bruker's Applied Mass Spectrometry division introduced the timsMetabo™ platform, designed for advanced small molecule analysis, particularly in the detection of per- and polyfluoroalkyl substances (PFAS) and other environmental contaminants.
A key development for Bruker is the integration of RECIPE’s diagnostic assay kits, ClinMass® and ClinDART®, with its EVOQ® DART-TQ system. This integration allows for enhanced therapeutic drug monitoring (TDM) and drugs of abuse (DoA) analysis, offering high-throughput, chromatography-free workflows that improve laboratory productivity and sustainability. The ClinDART® kits, designated for Research Use Only (RUO), provide rapid, cost-efficient analysis with reduced solvent usage.
The newly launched timsMetabo™ platform represents a significant leap forward in small molecule analysis. Built on Bruker's proprietary trapped ion mobility spectrometry (TIMS) technology, it features enhancements such as Mobility Range Enhancement (MoRE) and the Athena Ion Processor (AIP). Early studies indicate timsMetabo™ identifies 40% more low-mass molecules in water samples than previous-generation systems, supporting regulatory compliance and proactive environmental monitoring.
Bruker's majority investment in RECIPE further strengthens its applied markets leadership, and these advancements align with the company's goals of solving real-world analytical challenges in TDM and environmental analysis. As Bruker continues to develop solutions for PFAS, forensic toxicology, and therapeutic drug monitoring, the timsMetabo™ platform is set to support future applications, including low-mass drug metabolite detection and emerging contaminants.
Bruker Corporation remains a leader in high-performance scientific instruments and diagnostic solutions, enabling breakthroughs in post-genomic life science research and applied applications. With a strong focus on innovation and customer success, Bruker continues to make strides in analytical and diagnostic technologies across various sectors.
